← All trials
NCT05672836
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Apr 30, 2026
- First posted
- Jan 5, 2023
- Last posted
- Oct 10, 2023
- Enrollment
- 1040
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of UlsanLead sponsor
- University of UlsanSponsor investigator
- CardioVascular Research Foundation, KoreaCollaborator
- Daewoong Pharmaceutical Co. LTD.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.